LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
37 hedge funds and large institutions have $165M invested in LogicBio Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
33% more capital invested
Capital invested by funds: $124M → $165M (+$40.8M)
12% more funds holding
Funds holding: 33 → 37 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.18M |
| 2 |
BlackRock
New York
|
+$1.13M |
| 3 |
State Street
Boston,
Massachusetts
|
+$683K |
| 4 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
+$534K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$389K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.13M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$1.26M |
| 3 |
SCM
Sio Capital Management
New York
|
-$351K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$48.9K |
| 5 |
Morgan Stanley
New York
|
-$18.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $51K | -$9.82K | -740 | -16% |
|
27
Victory Capital Management
San Antonio,
Texas
| $39K | – | – | – |
|
28
Citigroup
New York
| $31K | +$3.25K | +245 | +12% |
|
|
SO
29
STRS Ohio
Columbus,
Ohio
| $28K | – | – | – |
|
30
JP Morgan Chase
New York
| $28K | +$4.17K | +314 | +16% |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $20K | +$12.1K | +914 | +150% |
|
32
UBS Group
Zurich,
Switzerland
| $20K | +$19.3K | +1,454 | +3,094% |
|
33
Legal & General Group
London,
United Kingdom
| $16K | – | – | – |
|
34
BNP Paribas Financial Markets
Paris,
France
| $12.5K | +$12.8K | +963 | New |
|
|
AIP
35
Ameritas Investment Partners
Lincoln,
Nebraska
| $9K | – | – | – |
|
36
Bank of Montreal
Toronto,
Ontario, Canada
| $9K | +$9.19K | +692 | New |
|
|
SFM
37
Sphera Funds Management
Tel Aviv,
Israel
| – | -$4.13M | -417,625 | Closed |
|
|
38
Morgan Stanley
New York
| – | -$18.7K | -1,411 | -98% |
|
LOGC Hedge Fund Activity: Q2 2019 in Review
37 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q2 2019, worth a combined $165M — up 33% from $124M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LOGC positions and 1 closed out — a net gain of 5 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $5.18M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $4.13M sold.
- 37 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q2 2019, up from 33 in Q1 2019.
- Funds reported $165M of LogicBio Therapeutics, Inc. Common Stock stock for Q2 2019, up 33% quarter-over-quarter.
- 6 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q2 2019 and 1 closed out, a net change of +5 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q2 2019 was Adage Capital Partners, an estimated $5.18M added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q2 2019 was Sphera Funds Management, an estimated $4.13M sold.
Based on aggregated 13F filings for Q2 2019.